Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain

References

• Magro F, Gionchetti P, Eliakim R, et al. European Crohn’s and Colitis Organisation [ecco]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670.
   PubMed Web of Science ®Google Scholar
• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019;94(7):1357–1373.
   PubMed Web of Science ®Google Scholar
• Marín-Jiménez I, Saro C, Díaz V, et al. Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study). Drugs Context. 2018;7:212505.
   PubMedGoogle Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31(7):693–707.
   PubMed Web of Science ®Google Scholar
• Taxonera C, Calvet X, Gisbert JP, et al. On behalf of COSCOL study investigators patient undergoing colectomy because of ulcerative colitis had a very high rate of surgical complications in clinical practice conditions. J Crohns Colitis. 2010;4(1):S59.
   Google Scholar
• Loftus EV, Delgado DJ, Friedman HS, et al. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103(7):1737–1745.
   PubMed Web of Science ®Google Scholar
• JW K, CK L, JK L, et al. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006–2015). Scand J Gastroenterol. 2019;54(4):419–426.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, EI EI, Lee L, et al. The Impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019;2(Suppl Supplement_1):S17–S33.
   PubMedGoogle Scholar
• Harbord M, Eliakim R, Bettenworth D, et al., European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
   PubMed Web of Science ®Google Scholar
• Strand V, Balsa A, Al-Salch J, et al. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. BioDrugs. 2017;31(4):299–316.
   PubMed Web of Science ®Google Scholar
• Van den Berghe N, Verstockt B, Tops S, et al. Immunogenicity is not the driving force of treatment failure in vedolizumab-treated inflammatory bowel disease patients. J Gastroenterol Hepatol. 2019;34(7):1175–1181.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):454–465.
   PubMed Web of Science ®Google Scholar
• Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gasteroenterol Hepatol. 2020;S1542-3565(20):30044–30046.
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. OCTAVE induction 1, OCTAVE induction 2, and OCTAVE sustain investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• INEbase [Internet]. Madrid: instituto nacional de estadística [Spanish National Statistics Institute (INE)]; 2001–2016. Available at: http://www.ine.es.
   Google Scholar
• Tappenden P, Ren S, Archer R, et al. Evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016;34(10):1023–1038.
   PubMed Web of Science ®Google Scholar
• Xie F, Blackhouse G, Assasi N, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;7(1):20.
   PubMedGoogle Scholar
• Caro JJ, Briggs AH, Siebert U, et al., Force I-SMGRPT. Modeling good research practices–overview: a report of the ISPOR-SMDM modeling good research practices task force–1. Value Health. 2012;15(6):796–803.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al.; ISPOR-SMDM modeling good research practices task force. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health. 2012;15: 812–820.
   Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–761.
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Campillo-Artero C, et al. What is an efficient health intervention in Spain in 2020? Gac Sanit. 2020;34(2):189–193.
   PubMed Web of Science ®Google Scholar
• Rubin D, Ashaye A, Zhang Y, et al. Efficacy of tofacitinib and biologics as induction and maintenance therapy for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. United European Gastroenterol J. 2018;6(8S):A252.
   Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. Erratum in: N Engl J Med. 2006;18;354(20):2200.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Cui HF, Gao J, et al. Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. J Clin Gastroenterol. 2015;49(7):582–588.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Barreiro-de Acosta M, Benítez J, et al. EpidemIBD group. P790 Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU. J Crohns Colitis. 2019;13(Supplement_1):S516–7.
   Google Scholar
• Peyrin-Biroulet L, Germain A, Patel AS, et al. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016 Oct;44(8):807–816.
   PubMed Web of Science ®Google Scholar
• Woehl A, Hawthorne A, McEwan P. The relation between disease activity, quality of life and health utility in patients with ulcerative colitis. Gut. 2008;57(Suppl. 1):A153.
   PubMedGoogle Scholar
• Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4(9):1135–1142.
   PubMed Web of Science ®Google Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos [Spanish General Council of Official Colleges of Pharmacists]. Conocimiento sanitario [healthcare knowledge] database - Bot PLUS 2.0 [internet]. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2019. Available at: https://botplusweb.portalfarma.com/.
   Google Scholar
• Oblikue Consulting. eSalud [eHealth] healthcare costs database [Internet]. Barcelona: Oblikue Consulting; 2019 [cited 20 Feb 2019]. Available at: http://www.oblikue.com/bddcostes/.
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios online Centro de Información de Medicamentos [Spanish Agency of Medicines and Medical Devices online Medicinal Products Information Centre] (AEMPS - CIMA). Madrid: agencia española de medicamentos y productos sanitarios; 2019. Available at: https://cima.aemps.es/cima/publico/home.html.
   Google Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad [Ministry of Health, Social Services and Equality]. Relación informativa de medicamentos afectados por las deducciones establecidas en el real decreto ley 8/2010 de 20 de mayo por el que se adoptan medidas extraordinarias para la reducción del déficit público [Informational list of medicines affected by the deductions established in Spanish Royal Decree/ Law 8/2010, of 20 May, adopting special measures to reduce the public deficit]. [Internet]. Madrid: Ministerio de Sanidad, Servicios Sociales e Igualdad; 2010. Available at: https://www.mscbs.gob.es/profesionales/farmacia/pdf/DeduccionesAbril19.pdf
   Google Scholar
• Taxonera C, Gisbert JP, Calvet X, et al. On behalf of COSCOL study investigators. Cost of colectomy in ulcerative colitis patients. Gut. 2009;58(Suppl II):A177.
   Google Scholar
• Ministerio de Sanidad, Servicios Sociales e Igualdad [Ministry of Health, Social Services and Equality]. Instituto de información sanitaria [Spanish healthcare information institute]. (2018). Record of discharges. CIE9 MC – CMBD 2015 [cited Jan2019]. Available at: http://pestadistico.inteligenciadegestion.mscbs.es/
   Google Scholar
• Cañas-Ventura A, Márquez L, Ricart E, et al. Spanish GETECCU group (ENEIDA project) risk of colectomy in patients with ulcerative colitis under thiopurine treatment. J Crohns Colitis. 2014;8(10):1287–1293.
   PubMed Web of Science ®Google Scholar
• Trigo-Vicente C, Gimeno-Ballester V, López-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm. 2020;27(6):355–360.
   PubMedGoogle Scholar
• Trigo-Vicente C, Ballester VG. Impacto presupuestario de la introducción de tofacitinib en el tratamiento de colitis ulcerosa moderada a grave [Budget impact of the introduction of tofacitinib in the treatment of moderate to severe ulcerative colitis]. In: Poster session presented at: 64th sociedad española de farmacia hospitalaria [Spanish hospital pharmacy association (SEFH)]. Spain: Seville; 2019 Oct. p. 17–19.
   Google Scholar
• Lohan C, Diamantopoulos A, LeReun C, et al. Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation. BMJ Open Gastroenterol. 2019;6(1):e000302.
   PubMed Web of Science ®Google Scholar
• Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2018;24(11):2291–2302.
   PubMed Web of Science ®Google Scholar
• Milev S, DiBonaventura MD, Quon P, et al. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. J Med Econ. 2019;22(9):859–868.
   PubMed Web of Science ®Google Scholar
• Vellopoulou K, Stefanou G, Tzanetakos C, et al. Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in Greece. Eur J Gastroenterol Hepatol. 2020. https://doi.org/10.1097/MEG.0000000000001916.
   Google Scholar
• Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol. 2020;13:1756284820941179.
   Web of Science ®Google Scholar
• Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20(6):752–761.
   PubMed Web of Science ®Google Scholar
• Cross KR. Which patients with inflammatory bowel disease should receive combination therapy? Expert Rev Gastroenterol Hepatol. 2015;9(6):715–717.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Peyrin-Biroulet L. Positioning therapies in ulcerative colitis. Clin Gasteroenterol Hepatol 2020;18(6):1280.e1.
   Web of Science ®Google Scholar